Matthias Luz
Dr. Luz joined ATAI Life Sciences to help transform the mental health space and work towards a cure for core neuropsychiatric disorders. Prior to joining ATAI, Dr. Luz served in various C-suite roles at numerous pharmaceutical companies such as Aventis, where he led the team that brought Refludan® (lepirudin), the first therapeutic for heparin-induced thrombocytopenia, to market worldwide. Dr. Luz...